Madhav Dhodapkar

Title: The Innovations of Madhav Dhodapkar

Introduction

Madhav Dhodapkar is a prominent inventor based in New Haven, CT, known for his significant contributions to the field of biomedical research. He holds a total of seven patents, showcasing his innovative approach to addressing complex medical challenges. His work primarily focuses on genetically modified non-human animals and methods for adoptive T cell therapy.

Latest Patents

One of Madhav Dhodapkar's latest patents involves genetically modified non-human animals that can model human hematopoietic cell development, function, or disease. These animals are engineered to express human IL-6, linked to an IL-6 promoter, and may also express other human proteins such as M-CSF, IL-3, GM-CSF, SIRPa, or TPO. In certain cases, these genetically modified animals are immunodeficient and can be engrafted with healthy or diseased human hematopoietic cells. Additionally, he has developed methods to mobilize tissue resident cells for adoptive T cell therapy, focusing on a subset of T cells known as SP T (T) cells, which exhibit a quiescent phenotype. His methods include obtaining and mobilizing T cells in subjects and utilizing them for adoptive cell transfer.

Career Highlights

Madhav Dhodapkar has had a distinguished career, working with esteemed institutions such as Yale University and Regeneron Pharmaceuticals, Inc. His research has significantly advanced the understanding of hematopoietic cell development and therapeutic applications.

Collaborations

Throughout his career, Madhav has collaborated with notable colleagues, including Richard A. Flavell and Till Strowig, contributing to a rich exchange of ideas and innovations in the field.

Conclusion

Madhav Dhodapkar's work exemplifies the intersection of innovation and practical application in biomedical research. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.